Expression of selected genes in preterm premature rupture of fetal membranes

Acta Obstet Gynecol Scand. 2012 Aug;91(8):936-43. doi: 10.1111/j.1600-0412.2012.01445.x. Epub 2012 Jun 27.

Abstract

Objective: To analyse the expression of 15 genes encoding receptors and enzymes associated with the molecular mechanism of the tocolytic drugs atosiban (oxytocin receptor antagonist), nifedipine (calcium channel blocker) and celecoxib (selective cyclo-oxygenase-2 inhibitor) in preterm labor patients with premature rupture of fetal membranes in relation to symptoms of intrauterine infection and preterm labor risk factors.

Design: Experimental molecular study.

Setting: Tertiary obstetric care center.

Sample: Myometrial samples were obtained during cesarean sections from 35 patients who delivered preterm with unverified symptoms of intrauterine infection, 35 patients who delivered preterm without symptoms of intrauterine infection and 90 women who delivered at term.

Methods: The Micro Fluidic Profiling Card analytic system was used to evaluate mRNA expression of the genes of interest.

Main outcome measures: The relative quantification values for mRNA expression.

Results: The median oxytocin receptor and cyclo-oxygenase-2 mRNA expression in preterm patients with clinical symptoms of intrauterine infection was significantly higher than in preterm patients without symptoms. The median mRNA expression of β(1) , β(3) and β(4) subunits of the L-type calcium channel and prostaglandin E(2) receptor was significantly higher in preterm patients compared with term patients.

Conclusions: The mRNA expression of hormones, enzymes and their receptors associated with tocolytic actions can differ in various clinical conditions. The expression of these genes is regulated at different levels and can be modified by inflammatory factors, which affect their functions.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Calcium Channel Blockers / pharmacology
  • Calcium Channels, L-Type / genetics
  • Calcium Channels, L-Type / metabolism*
  • Celecoxib
  • Cyclooxygenase 2 Inhibitors / pharmacology
  • Dinoprostone / genetics
  • Dinoprostone / metabolism*
  • Endometritis / microbiology
  • Female
  • Fetal Membranes, Premature Rupture / metabolism*
  • Gene Expression Profiling*
  • Gene Expression Regulation, Developmental
  • Humans
  • Nifedipine / pharmacology
  • Obstetric Labor, Premature / drug therapy*
  • Obstetric Labor, Premature / metabolism*
  • Oxytocics / pharmacology
  • Pregnancy
  • Pregnancy Trimester, Second
  • Pregnancy Trimester, Third
  • Premature Birth / drug therapy
  • Premature Birth / metabolism
  • Pyrazoles / pharmacology
  • RNA, Messenger / metabolism
  • Sulfonamides / pharmacology
  • Term Birth / metabolism
  • Tocolytic Agents / pharmacology*
  • Tocolytic Agents / therapeutic use
  • Vasotocin / analogs & derivatives
  • Vasotocin / pharmacology

Substances

  • Calcium Channel Blockers
  • Calcium Channels, L-Type
  • Cyclooxygenase 2 Inhibitors
  • Oxytocics
  • Pyrazoles
  • RNA, Messenger
  • Sulfonamides
  • Tocolytic Agents
  • atosiban
  • Nifedipine
  • Celecoxib
  • Dinoprostone
  • Vasotocin